` 688013 (Touchstone International Medical Science Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

T
688013
vs
S
Shanghai Composite

Over the past 12 months, Touchstone International Medical Science Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +124% compared to the Shanghai Composite's +24% growth.

Stocks Performance
688013 vs Shanghai Composite

Loading
688013
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
688013 vs Shanghai Composite

Loading
688013
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
688013 vs Shanghai Composite

Loading
688013
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Touchstone International Medical Science Co Ltd vs Peers

Shanghai Composite
688013
MTWO
XLO
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Touchstone International Medical Science Co Ltd
Glance View

Market Cap
3.5B CNY
Industry
Health Care

Touchstone International Medical Science Co., Ltd. specializes in the development of advanced and innovative surgical devices that enhance clinical performance, mini-mize risk, and improve patient outcomes. The company is headquartered in Suzhou, Jiangsu and currently employs 206 full-time employees. The company went IPO on 2020-09-28. The firm's products include tubular staplers, endoscopic staplers, linear cutting staplers, purse-string staplers and linear suture staplers. Its products are used in the surgical fields of cardiothoracic surgery, gastrointestinal surgery, hepatobiliary spleen and pancreatic surgery, general surgery and urology. The firm conducts its businesses within the China market and to overseas markets such as Italy, Spain, Austria, Brazil, South Korea, the United Kingdom and Australia.

Intrinsic Value
19.54 CNY
Overvaluation 54%
Intrinsic Value
Price
T
Back to Top